LOS ANGELES (CN) – Mylan Pharmaceuticals claims poor legal work on antitrust issues by attorneys with Ervin, Cohen & Jessup cost it $216 million. The issues involved deal with generic drug supplier Profarmaco that raised the prices of lorazepam and clorazepate by 1,900 to 3,200 percent, leading to an FTC investigation. Mylan is represented in Superior Court by Parker Mills Morin.
- 4th Circuit
- Shareholder Class Action